Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer-Reference-Cited by-同舟云学术

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

Published:2014-01 Issue:1 Volume:25 Page:121-126
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Blaszkowsky L.S.,Ryan D.P.,Szymonifka J.,Borger D.R.,Zhu A.X.,Clark J.W.,Kwak E.L.,Mamon H.J.,Allen J.N.,Vasudev E.,Shellito P.C.,Cusack J.C.,Berger D.L.,Hong T.S.

Funder

Genentech

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/1/121/395502/mdt516.pdf

Reference29 articles.

1. Preoperative versus postoperative chemoradiotherapy for rectal cancer;Sauer;N Engl J Med,2004

2. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer;Rodel;J Clin Oncol,2005

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004